Consensus Guidelines for Interventional Cardiology Services Delivery During COVID-19 Pandemic in Australia and New Zealand
Type
ArticleAuthor/s
Lo, S.T.H.Yong, A.S.
Sinhal, A.
Shetty, S.
McCann, A.
Clark, D.
Galligan, L.
El-Jack, S.
Sader, M.
Tan, R.
Hallani, H.
Barlis, P.
Sechi, R.
Dictado, E.
Walton, A.
Starmer, G.
Bhagwandeen, R.
Leung, D.Y.
Juergens, C.P.
Bhindi, R.
Muller, D.W.M.
Rajaratnum, R.
French, J.K.
Kritharides, L.
group, on behalf of the Interventional council of CSANZ and COVID-19 Interventional cardiology working
Abstract
The global COVID-19 pandemic poses an unprecedented stress on healthcare systems internationally. These Health system-wide demands call for efficient utilisation of resources at this time in a fair, consistent, ethical and efficient manner would improve our ability to treat patients. ...
See moreThe global COVID-19 pandemic poses an unprecedented stress on healthcare systems internationally. These Health system-wide demands call for efficient utilisation of resources at this time in a fair, consistent, ethical and efficient manner would improve our ability to treat patients. Excellent co-operation between hospital units (especially ICU, ED and cardiology) is critical in ensuring optimal patient outcomes. The purpose of this document is to provide practical guide lines for the effective use of interventional cardiology services in Australia and New Zealand. The document will be updated regularly as new evidence and knowledge is gained 55 with time.
See less
See moreThe global COVID-19 pandemic poses an unprecedented stress on healthcare systems internationally. These Health system-wide demands call for efficient utilisation of resources at this time in a fair, consistent, ethical and efficient manner would improve our ability to treat patients. Excellent co-operation between hospital units (especially ICU, ED and cardiology) is critical in ensuring optimal patient outcomes. The purpose of this document is to provide practical guide lines for the effective use of interventional cardiology services in Australia and New Zealand. The document will be updated regularly as new evidence and knowledge is gained 55 with time.
See less
Date
2020Funding information
AstraZeneca (United Kingdom)
Abbott (United States)
Medtronic (United States)
Edwards Lifesciences (United States)
Boehringer Ingelheim (United States)
Bayer (United States)
Boston Scientific (United States)
Pfizer (United States)
Licence
OtherFaculty/School
Faculty of Medicine and Health, Sydney Medical SchoolShare